Listed

Integer Holdings Corp: Form 10-Q for the period ended Sep 28, 2018

Filed with the SEC on Nov 2, 2018 and accepted by EDGAR at Nov 2, 2018, 16:30 ET.

Share

Management's discussion and analysis

As filed, 62,208 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

This Quarterly Report on Form 10-Q should be read in conjunction with the disclosures included in our Annual Report on Form 10-K for the fiscal year ended December 29, 2017. In addition, please read this section in conjunction with our Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements contained herein.

Forward-Looking Statements

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include statements relating to:

  • future sales, expenses, and profitability;
  • future development and expected growth of our business and industry;
  • our ability to execute our business model and our business strategy;
  • our ability to identify trends within our industries and to offer products and services that meet the changing needs of those markets;
  • our ability to remain in compliance with the financial covenants contained in the agreement governing our Senior Secured Credit Facilities; and
  • projected capital expenditures.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or “variations” or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: our high level of indebtedness, our inability to pay principal and interest on this high level of outstanding indebtedness or to remain in compliance with financial and other covenants under our Senior Secured Credit Facilities, and the risk that this high level of indebtedness limits our ability to invest in our business and overall financial flexibility; our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing pressure from customers; our ability to timely and successfully implement cost savings and consolidation initiatives; our reliance on third party suppliers for raw materials, products and subcomponents; fluctuating operating results; our inability to maintain high quality standards for our products; challenges to our intellectual property rights; product liability claims; product field actions or recalls; our inability to successfully consummate and integrate acquisitions and to realize synergies and to operate these acquired businesses in accordance with expectations; our unsuccessful expansion into new markets; our failure to develop new products; the timing, progress and ultimate success of pending regulatory actions and approvals; our inability to obtain licenses to key technology; regulatory changes, including health care reform, or consolidation in the healthcare industry; global economic factors, including currency exchange rates and interest rates; the resolution of various legal actions brought against the Company; enactment related and ongoing impacts related to the U.S. Tax Cuts and Jobs Act (the “Tax Reform Act”), including the Global Intangible Low-Taxed Income (“GILTI”) tax; and other risks and uncertainties that arise from time to time and are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in other periodic filings with the Securities and Exchange Commission. Except as required by applicable law, the Company assumes no obligation to update forward-looking statements in this report whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

  • 33 -

Our Business

Integer Holdings Corporation is one of the largest medical device outsource (“MDO”) manufacturers in the world serving the cardiac, neuromodulation, vascular and portable medical markets. We also develop batteries for high-end niche applications in the non-medical energy, military, and environmental markets. Our vision is to enhance the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

We organize our business into two reportable segments, Medical and Non-Medical, and derive our revenues from four principle product lines. The Medical segment includes the Advanced Surgical, Orthopedics & Portable Medical, Cardio & Vascular and Cardiac & Neuromodulation product lines and the Non-Medical segment is comprised of the Electrochem product line.

Discontinued Operations and Divestiture

On May 3, 2018, the Company entered into a definitive agreement to sell the Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) within its Medical segment to Viant (formerly MedPlast, LLC). On July 2, 2018, we completed the sale of the AS&O Product Line for net cash proceeds of approximately $582 million, resulting in a pre-tax gain of approximately $195 million. As a result, we classified the results of operations of the AS&O Product Line as discontinued operations in the Condensed Consolidated Statements of Operations for all periods presented and classified the related assets and liabilities associated with the discontinued operations as held for sale in the Condensed Consolidated Balance Sheet as of December 29, 2017. All results and information presented exclude the AS&O Product Line unless otherwise noted. Refer to Note 2 “Discontinued Operations and Divestiture” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about the divestiture.

In connection with the sale, the parties executed a transition services agreement whereby we will provide certain corporate services (including accounting, payroll, and information technology services) to Viant for a period of up to one year from the date of the closing to facilitate an orderly transfer of business operations. Viant will pay us for these services, with such payments varying in amount and length of time as specified in the transition services agreement. In addition, the parties executed long-term supply agreements under which the parties have agreed to supply the other with certain products at prices specified in the agreements for a term of three years.

Strategic Overview

During 2017, we undertook a thorough strategic review of our customers, competitors and markets. As a result of this review, during the fourth quarter of 2017, we began to take steps to better align our resources in order to invest to grow, protect, preserve and to enhance the profitability of our portfolio of products. These steps include focusing our investment in research and development and manufacturing, improving our business processes and redirecting investments away from projects where the market does not justify the investment. The execution of this strategy will be our primary focus going forward.

We believe Integer is well-positioned within the medical technology and MDO manufacturing market and that there is a robust pipeline of opportunities to pursue. We have expanded our medical device capabilities and are excited about opportunities to partner with customers to drive innovation. We believe we have the scale and global presence, supported by world-class manufacturing and quality capabilities, to capture these opportunities. We are confident in our abilities as one of the largest MDO manufacturers, with a long history of successfully integrating companies, driving down costs and growing revenues over the long-term. Ultimately, our strategic vision is to drive shareholder value by enhancing the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

  • 34 -

Revised 2018 Outlook(a)

(dollars in millions, except per share amounts)

GAAP Non-GAAP(b)
Continuing Operations: As Reported Growth Adjusted Growth
Sales $1,197 to $1,212 5% to 7% $1,195 to $1,210 6% to 7%
Net Income $44 to $49 (50)% to (44)% $117 to $122 18% to 23%
EBITDA N/A N/A $255 to $265 9% to 13%
Earnings per Diluted Share $1.34 to $1.49 (51)% to (46)% $3.55 to $3.70 15% to 20%

(a) Except as described below, further reconciliations by line item to the closest corresponding GAAP financial measure for Adjusted Sales, Adjusted Net Income, Adjusted EBITDA, and Adjusted Earnings per Diluted Share, included in our “Revised 2018 Outlook” above, are not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and visibility of the charges excluded from these non-GAAP financial measures.

(b) Adjusted Net Income and EPS for 2018 is expected to consist of GAAP Net Income and EPS, excluding items such as intangible amortization, IP-related litigation costs, consolidation and realignment costs, asset disposition and write-down charges, and loss on extinguishment of debt totaling approximately $89 million. The after-tax impact of these items is estimated to be approximately $70 million, or approximately $2.13 per diluted share. Additionally, Adjusted Net Income and EPS is expected to exclude the estimated impact relating to our disallowed deduction of the GILTI tax, as mandated by the Tax Reform Act. This disallowed deduction of the GILTI tax (approximately 50% of the total GILTI tax) is due to the Company making use of its U.S. net operating losses (“NOLs”), and will be eliminated once the Company’s U.S. NOLs are fully utilized, which is expected to be in 2019. This adjustment makes our Adjusted Diluted EPS more comparable with other global companies that are not subject to this disallowed GILTI tax deduction and more comparable to the Company’s results following the full utilization of its U.S. NOLs.

Adjusted EBITDA is expected to consist of Adjusted Net Income, excluding items such as depreciation, interest, stock-based compensation and taxes totaling approximately $140 million.

  • 35 -

Financial Overview of Continuing Operations

Loss from continuing operations for the third quarter of 2018 was $8.3 million, or $0.26 per diluted share, compared to income from continuing operations of $19.9 million, or $0.62 per diluted share, for the third quarter of 2017. Income from continuing operations for the first nine months of 2018 was $27.8 million, or $0.86 per diluted share, compared to income from continuing operations of $32.4 million, or $1.01 per diluted share, for the first nine months of 2017. These year over year variances are primarily the result of the following:

  • Sales from continuing operations for the third quarter and first nine months of 2018 increased 7% and 9%, respectively, primarily driven by market growth and new business wins. In comparison to the prior year periods, foreign currency exchange rates decreased sales by $0.1 million for the third quarter of 2018 and increased sales from continuing operations by approximately $2.3 million for the first nine months of 2018.
  • Gross profit from continuing operations for the third quarter and first nine months of 2018 increased $2.7 million and $13.8 million, respectively, primarily due to the increase in sales from continuing operations discussed above, partially offset by higher incentive compensation based upon current year-to-date results.
  • Operating expenses for the third quarter and first nine months of 2018 were lower by $2.9 million and $6.2 million, respectively, compared to the same periods in 2017, due to a decrease in other operating expenses attributable to the completion of spending on integration activities and various efficiencies and synergies gained as a result of our integration and consolidation initiatives partially offset by higher incentive compensation.
  • Interest expense for the third quarter and first nine months of 2018 increased by $38.7 million and $36.1 million, respectively, compared to the same periods in 2017, primarily due to extinguishment of debt charges related to the repayment of indebtedness in connection with the divestiture of the AS&O Product Line. Debt extinguishment expenses included in interest expense for the third quarter and first nine months of 2018 were higher by $39.9 million and $38.9 million, respectively, compared to the same periods in 2017.
  • Net gains on cost and equity method investments, which are unpredictable in nature, increased income for the third quarter and first nine months of 2018 by $0.3 million and $5.5 million, respectively, compared to income of $1.9 million and losses of $2.9 million during the same periods in 2017.
  • Other loss, net for the third quarter and first nine months of 2018 was $1.7 million and $0.3 million, respectively, compared to $2.5 million and $10.7 million during the same periods in 2017, primarily due to the non-recurrence of a non-cash foreign currency charge in the prior year on inter-company loans.
  • We recorded an income tax benefit of $6.2 million for the third quarter of 2018, compared to a benefit of $0.4 million for the same period of 2017. The income tax provision for the first nine months of 2018 and 2017 was $8.0 million and $0.6 million, respectively. Refer to Note 9 “Income Taxes” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report and the “Provision for Income Taxes” section of this Item for additional information.
  • 36 -

Use of Non-GAAP Financial Information

We prepare our condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Additionally, we report and discuss in our earnings releases and investor presentations adjusted pre-tax income, adjusted income, adjusted earnings per diluted share, earnings before interest, taxes, depreciation, and amortization (“EBITDA”), adjusted EBITDA and organic sales growth rates, all from continuing operations. Adjusted pre-tax income, adjusted income and adjusted earnings per diluted share from continuing operations consist of GAAP amounts adjusted for the following to the extent occurring during the period: (i) acquisition and integration related charges and expenses, (ii) amortization of intangible assets including inventory step-up amortization, (iii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iv) asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain litigation expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) gain/loss on cost and equity method investments, (ix) extinguishment of debt charges, (x) the net impact of Long-term Supply Agreements (“LSAs”) between the Company and Viant, (xi) the income tax (benefit) related to these adjustments and (xii) certain tax items that are outside the normal provision for the period (not for adjusted pre-tax income). Adjusted earnings per diluted share are calculated by dividing adjusted income from continuing operations by diluted weighted average shares outstanding. Adjusted EBITDA from continuing operations consists of GAAP net income (loss) from continuing operations plus (i) the same adjustments as listed above except for items (xi) and (xii), (ii) GAAP stock-based compensation, interest expense, and depreciation and (iii) GAAP provision (benefit) for income taxes. To calculate organic sales growth rates, which exclude the impact of changes in foreign currency exchange rates, as well as the impact of any acquisitions or divestitures of product lines on sales growth rates, we convert current period sales from local currency to U.S. dollars using the previous periods foreign currency exchange rates and exclude the amount of sales acquired/divested during the period from the current/previous period amounts, respectively. We believe that the presentation of adjusted income, adjusted diluted earnings per share, EBITDA, adjusted EBITDA, and organic sales growth rates, all from continuing operations, provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations.

  • 37 -

Income (Loss) from Continuing Operations and Diluted EPS Reconciliations

A reconciliation of GAAP income from continuing operations and diluted earnings per share (“EPS”) from continuing operations to adjusted amounts is as follows (in thousands, except per share amounts):

Three Months Ended September 28, 2018 Pre-Tax Income (Loss) Income (Loss) Per Diluted Share September 29, 2017 Pre-Tax Income (Loss) Income (Loss) Per Diluted Share
As reported income from continuing operations (GAAP) $(14,460) $(8,303) $(0.26) $19,434 $19,882 $0.62
Adjustments:
Amortization of intangibles(a) 9,896 7,830 0.24 10,145 7,103 0.22
IP related litigation (SG&A)(a)(b) 749 591 0.02 1,735 1,128 0.04
Strategic reorganization and alignment (OOE)(a)(c) 2,643 2,085 0.06 — — —
Manufacturing alignment to support growth (OOE)(a)(d) 877 657 0.02 — — —
Consolidation and optimization expenses (OOE)(a)(e) 137 108 — 2,979 2,630 0.08
Acquisition and integration expenses (OOE)(a)(f) — — — 2,267 1,106 0.03
Asset dispositions, severance and other (OOE)(a)(g) 482 412 0.01 823 546 0.02
(Gain) loss on cost and equity method investments, net(a) (291) (230) (0.01) (1,906) (1,239) (0.04)
Loss on extinguishment of debt(a)(h) 40,654 32,117 0.98 778 506 0.02
LSA adjustments(a)(i) — — — (3,450) (2,242) (0.07)
Tax adjustments(j) — (417) (0.01) — — —
Adjusted income from continuing operations (Non-GAAP) $40,687 $34,850 $1.06 $32,805 $29,420 $0.91
Diluted weighted average shares for adjusted EPS 32,899 32,173
Nine Months Ended
September 28, 2018 September 29, 2017
Pre-Tax Income (Loss) Income (Loss) Per Diluted Share Pre-Tax Income (Loss) Income (Loss) Per Diluted Share
As reported income from continuing operations (GAAP) $35,793 $27,837 $0.86 $32,985 $32,389 $1.01
Adjustments:
Amortization of intangibles(a) 31,068 24,523 0.75 30,375 21,205 0.66
IP related litigation (SG&A)(a)(b) 1,546 1,221 0.04 3,027 1,968 0.06
Strategic reorganization and alignment (OOE)(a)(c) 8,424 6,662 0.20 — — —
Manufacturing alignment to support growth (OOE)(a)(d) 2,493 1,841 0.06 — — —
Consolidation and optimization expenses (OOE)(a)(e) 698 553 0.02 8,055 6,525 0.20
Acquisition and integration expenses (OOE)(a)(f) — — — 10,057 6,276 0.20
Asset dispositions, severance and other (OOE)(a)(g) 1,000 776 0.02 6,378 4,144 0.13
(Gain) loss on cost and equity method investments, net(a) (5,545) (4,381) (0.13) 2,919 1,897 0.06
Loss on extinguishment of debt(a)(h) 42,128 33,281 1.02 3,272 2,127 0.07
LSA adjustments(a)(i) (6,119) (4,834) (0.15) (9,361) (6,084) (0.19)
Tax adjustments(j) — 2,534 0.08 — — —
Adjusted income from continuing operations (Non-GAAP) $111,486 $90,013 $2.75 $87,707 $70,447 $2.21
Diluted weighted average shares for adjusted EPS 32,681 31,947
  • 38 -

(a) The difference between pre-tax and income (loss) amounts is the estimated tax impact related to the respective adjustment. Income (loss) amounts are computed using a 21% U.S. tax rate (35% U.S. tax rate for 2017 periods), and the statutory tax rates in Mexico, Netherlands, Uruguay, Ireland and Switzerland, as adjusted for the existence of NOLs. Amortization of intangibles and OOE expense have also been adjusted to reflect the estimated impact relating to our disallowed deduction of the GILTI tax, as described in footnote (j) below. Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.

(b) In 2013, we filed suit against AVX Corporation alleging they were infringing our intellectual property. Given the complexity and significant costs incurred pursuing this litigation, we are excluding these litigation expenses from adjusted amounts. This matter proceeded to trial during the first quarter of 2016 and again in the third quarter of 2017 that resulted in a jury awarding damages in the amount of $37.5 million. In March 2018, the court vacated that damage award and ordered a new trial on damages, which is scheduled for January 2019. To date, no gains have been recognized in connection with this litigation.

(c) As a result of the strategic review of our customers, competitors and markets we undertook during the fourth quarter of 2017, we began to take steps to better align our resources in order to invest to grow, protect, preserve and to enhance the profitability of our portfolio of products. This will include focusing our investment in RD&E and manufacturing, improving our business processes and redirecting investments away from projects where the market does not justify the investment. As a result, during 2018 we incurred charges related to this strategy, which primarily consisted of severance costs and fees for professional services.

(d) In 2017, we initiated several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of our facilities.

(e) During 2018 and 2017, we incurred costs primarily related to the closure of our Clarence, NY facility and the transfer of our Beaverton, OR portable medical and Plymouth, MN vascular manufacturing operations to Tijuana, Mexico.

(f) Reflects acquisition and integration costs related to the acquisition of Lake Region Medical, which occurred in October 2015.

(g) Amounts for 2017 primarily include expenses related to our CEO and CFO transitions.

(h) Represents debt extinguishment charges in connection with pre-payments made on our Term B Loan Facility and Senior Notes, which are included in interest expense. In addition, the 2018 periods include a “make-whole” premium of $31.3 million, paid as a result of redeeming our Senior Notes in July 2018.

(i) Reflects the net impact of the LSAs entered into as of the closing of the divestiture of the AS&O Product Line. These LSAs govern the sale of products supplied by Viant to the Company for further resale to customers and by the Company to Viant for further resale to customers.

(j) Tax adjustments primarily includes the estimated impact relating to our disallowed deduction of the GILTI tax, as mandated by the Tax Reform Act. This disallowed deduction of the GILTI tax (approximately 50% of the total GILTI tax) is due to the Company making use of its U.S. NOLs, and will be eliminated once the Company’s U.S. NOLs are fully utilized, which is expected to be in 2019. This adjustment makes our Adjusted Diluted EPS from continuing operations more comparable with other global companies that are not subject to this disallowed GILTI tax deduction and more comparable to the Company’s results following the full utilization of its U.S. NOLs.

  • 39 -

Adjusted diluted EPS from continuing operations, which excludes the impact of amortization of intangible assets, losses on extinguishment of debt and various other operating expenses, among others, was $1.06 and $2.75 per share for the third quarter and first nine months of 2018, respectively, compared to $0.91 and $2.21 per share for the third quarter and first nine months of 2017, respectively. These results reflect the benefit of our increased sales and the completion of spending on integration activities, partially offset by higher incentive compensation and higher interest expense in 2018 compared to 2017.

EBITDA and Adjusted EBITDA Reconciliation

A reconciliation of GAAP income from continuing operations to EBITDA from continuing operations and adjusted EBITDA from continuing operations is as follows (dollars in thousands):

Three Months Ended September 28, 2018 September 29, 2017 Nine Months Ended September 28, 2018 September 29, 2017
Income (loss) from continuing operations (GAAP) $(8,303) $19,882 $27,837 $32,389
Interest expense 54,526 15,808 85,355 49,233
Provision for income taxes (6,157) (448) 7,956 596
Depreciation 9,960 9,534 29,929 28,262
Amortization 9,896 10,145 31,068 30,375
EBITDA from continuing operations 59,922 54,921 182,145 140,855
IP related litigation 749 1,735 1,546 3,027
Stock-based compensation (excluding OOE) 2,087 2,041 7,265 7,116
Strategic reorganization and alignment 2,643 — 8,424 —
Manufacturing alignment to support growth 877 — 2,493 —
Consolidation and optimization expenses 137 2,979 698 8,055
Acquisition and integration expenses — 2,267 — 10,057
Asset dispositions, severance and other 482 823 1,000 6,378
Non-cash (gain) loss on cost and equity method investments (291) (992) (5,545) 3,833
LSA adjustments $— $(3,450) $(6,119) $(9,361)
Adjusted EBITDA from continuing operations (Non-GAAP) $66,606 $60,324 $191,907 $169,960

Our CEO’s View

We delivered another solid quarter of sales growth, leading to another increase in our revenue and EPS guidance. We also reduced our debt dramatically during the quarter and lowered our debt leverage ratio from the beginning of the year.

At the beginning of the fourth quarter we hired Jason Garland as our new Executive Vice President and Chief Financial Officer. Jason brings nearly 25 years of public company, global financial leadership experience and significant manufacturing and customer contract expertise to Integer.

With the executive leadership team in place, we are focused on executing our portfolio strategy to win in the markets we serve and our operational strategy to achieve excellence in everything we do. We remain in a strong position to deliver on our long-term objectives of sales growth above the market, profit growth two times sales growth, and earning a valuation premium.

  • 40 -

Cost Savings and Consolidation Efforts

In 2018 and 2017, we recorded charges in Other Operating Expenses related to various cost savings and consolidation initiatives. These initiatives were undertaken to improve our operational efficiencies and profitability, the most significant of which are as follows (dollars in millions):

Initiative Expected Expense Expected Capital Expenditures Expected Annual Cost Savings(a) Expected Completion Date
Strategic reorganization and alignment $28 - $30(b) - $8 - $12 2018
Manufacturing alignment to support growth $9 - $11 $4 - $6 $2 - $3 2019
Consolidation and optimization expenses $18 - $22(b) $5 - $6 $12 - $13 2018

(a) Represents the annual benefit to our operating income expected to be realized from these initiatives through cost savings and/or increased capacity. These benefits will be phased in over time as the various initiatives are completed, some of which are already included in our current period results.

(b) Expected expense for these initiatives include amounts classified as discontinued operations.

We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion. Future charges are expected to be incurred as we seek to create an optimized manufacturing footprint, leveraging our increased scale and product capabilities while also supporting the needs of our customers. Our efforts will include:

  • potential manufacturing consolidations;
  • continuous improvement;
  • productivity initiatives;
  • direct material and indirect expense savings opportunities; and
  • the establishment of centers of excellence.

Refer to Note 8 “Other Operating Expenses” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about the timing, cash flow impact, and amount of future expenditures for our cost savings and consolidation initiatives.

  • 41 -

Our Financial Results of Continuing Operations

We utilize a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. For 52-week years, each quarter contains 13 weeks. The third quarter and first nine months of 2018 and 2017 ended on September 28 and September 29, respectively, and each contained 13 weeks and 26 weeks, respectively.

The following tables present selected financial information from continuing operations derived from our Condensed Consolidated Financial Statements, contained in Item 1 of this report, for the periods presented (dollars in thousands, except per share). All financial information presented is from continuing operations unless otherwise specified.

Medical Sales: Three Months Ended September 28, 2018 September 29, 2017 Change $%
Cardio & Vascular $150,230 $137,712 $12,518 9.1%
Cardiac & Neuromodulation 109,620 101,612 8,008 7.9%
Advanced Surgical, Orthopedics & Portable Medical 32,789 31,715 1,074 3.4%
Total Medical Sales 292,639 271,039 21,600 8.0%
Non-Medical 12,449 15,129 (2,680) (17.7)%
Total Sales 305,088 286,168 18,920 6.6%
Cost of sales 213,165 196,982 16,183 8.2%
Gross profit 91,923 89,186 2,737 3.1%
Gross profit as a % of sales 30.1% 31.2%
SG&A 34,091 35,064 (973) (2.8)%
SG&A as a % of sales 11.2% 12.3%
RD&E 12,234 12,227 7 0.1%
RD&E as a % of sales 4.0% 4.3%
Other operating expenses 4,139 6,069 (1,930) (31.8)%
Operating income 41,459 35,826 5,633 15.7%
Operating margin 13.6% 12.5%
Interest expense 54,526 15,808 38,718 NM
Gain on cost and equity method investments, net (291) (1,906) 1,615 (84.7)%
Other loss, net 1,684 2,490 (806) (32.4)%
Income (loss) from continuing operations before income taxes (14,460) 19,434 (33,894) NM
Benefit for income taxes (6,157) (448) (5,709) NM
Effective tax rate 42.6% (2.3)%
Income (loss) from continuing operations $(8,303) $19,882 $(28,185) NM
Income (loss) from continuing operations as a % of sales (2.7)% 6.9%
Diluted earnings (loss) per share from continuing operations $(0.26) $0.62 $(0.88) NM
  • 42 -

MANAGEMENT'S DISCUSSION AND ANALYSIS

Medical Sales: Nine Months Ended September 28, 2018 September 29, 2017 Change $%
Cardio & Vascular $435,859 $391,914 $43,945 11.2%
Cardiac & Neuromodulation 334,471 311,540 22,931 7.4%
Advanced Surgical, Orthopedics & Portable Medical 101,481 88,148 13,333 15.1%
Total Medical Sales 871,811 791,602 80,209 10.1%
Non-Medical 40,167 42,218 (2,051) (4.9)%
Total Sales 911,978 833,820 78,158 9.4%
Cost of sales 637,758 573,431 64,327 11.2%
Gross profit 274,220 260,389 13,831 5.3%
Gross profit as a % of sales 30.1% 31.2%
SG&A 107,300 105,004 2,296 2.2%
SG&A as a % of sales 11.8% 12.6%
RD&E 38,445 35,104 3,341 9.5%
RD&E, Net as a % of sales 4.2% 4.2%
Other operating expenses 12,615 24,490 (11,875) (48.5)%
Operating income 115,860 95,791 20,069 21.0%
Operating margin 12.7% 11.5%
Interest expense 85,355 49,233 36,122 73.4%
(Gain) loss on cost and equity method investments, net (5,545) 2,919 (8,464) NM
Other loss, net 257 10,654 (10,397) (97.6)%
Income from continuing operations before income taxes 35,793 32,985 2,808 8.5%
Provision for income taxes 7,956 596 7,360 NM
Effective tax rate 22.2% 1.8%
Income from continuing operations $27,837 $32,389 $(4,552) (14.1)%
Income from continuing operations as a % of sales 3.1% 3.9%
Diluted earnings per share from continuing operations $0.86 $1.01 $(0.15) (14.9)%

NM Calculated amount not meaningful

  • 43 -

Product Line Sales of Continuing Operations Highlights

For the third quarter and first nine months of 2018, Cardio & Vascular sales increased $12.5 million, or 9% and $43.9 million or 11%, respectively, versus the comparable 2017 periods. These increases were primarily due to continued strong demand in the electrophysiology market stemming from customer share gains, new product launches, and timing from customer inventory replenishment. The Cardio & Vascular growth trend is expected to remain above market from increased focus on high growth market segments. Foreign currency exchange rate fluctuations decreased Cardio & Vascular sales for the three months ended September 28, 2018 by $0.1 million and increased Cardio & Vascular sales by $2.3 million for the nine months ended September 28, 2018, respectively, in comparison to the 2017 periods primarily due to U.S. dollar fluctuations relative to the Euro.

For the third quarter and first nine months of 2018, Cardiac & Neuromodulation sales increased $8.0 million, or 8% and $22.9 million, or 7%, respectively, versus the comparable 2017 periods. The increases in Cardiac & Neuromodulation sales were driven by increased components market penetration and lower 2017 comparables from customer inventory adjustments. Neuromodulation remained strong, with growth driven by spinal cord stimulation market demand and increased components market penetration. Cardiac & Neuromodulation sales are expected to decrease in the fourth quarter of 2018 compared to extremely strong fourth quarter of 2017. Foreign currency exchange rate fluctuations did not have a material impact on Cardiac & Neuromodulation sales during the 2018 periods in comparison to the same periods of 2017.

Advanced Surgical, Orthopedic & Portable Medical includes sales to the acquirer of our AS&O Product Lines, Viant, under supply agreements associated with the divestiture. For the third quarter and first nine months of 2018, AS&O sales increased $1.1 million, or 3%, and $13.3 million, or 15%, respectively, versus the comparable 2017 periods. The sales increase was driven by above market demand. Sales are expected to level off from strong first half and growth is expected to be more in line with the overall market. Foreign currency exchange rate fluctuations did not have a material impact on AS&O sales during the 2018 periods in comparison to the same periods of 2017.

For the third quarter and first nine months of 2018, Non-Medical sales decreased $2.7 million, or 18% and $2.1 million, or 5%, respectively, versus the comparable 2017 periods. The decline in Non-Medical sales was primarily due to North American drilling activity leveling off which has led to customer inventory adjustments. The quarter was also impacted by a planned phase out of certain rechargeable battery pack products. We expect fourth quarter 2018 year-over-year sales to be flat and we expect solid sales growth in 2019 from new customers and products, and renewed military market government funding. Foreign currency exchange rate fluctuations did not have a material impact on Non-Medical sales during the 2018 periods in comparison to the same periods of 2017.

Gross Profit

Changes to gross profit as a percentage of sales (“Gross Margin”) from the prior year were due to the following:

Change From Prior Year Three Months Nine Months
Price(a) (1.4)% (1.3)%
Mix(b) — (0.2)
Incentive compensation(c) (0.7) (0.6)
Production efficiencies and volume(d) 1.0 1.0
Total percentage point change to gross profit as a percentage of sales (1.1)% (1.1)%

(a) Our Gross Margin for the third quarter and first nine months of 2018 has been negatively impacted by price concessions given to our larger OEM customers in return for long-term volume commitments.

(b) Our Gross Margin for the first nine months of 2018 has been negatively impacted by a higher mix of sales of lower margin products.

(c) Amounts represent the impact to our Gross Margin attributable to our cash and stock incentive programs, including performance-based compensation, which is accrued based upon actual results achieved.

(d) Represents various increases and decreases to our Gross Margin. Overall, our Gross Margin for the third quarter and first nine months of 2018 has been positively impacted by production efficiencies and synergies gained as a result of our integration and consolidation initiatives as well as higher volume in comparison to the respective 2017 period.

  • 44 -

SG&A Expenses

Changes to SG&A expenses from the prior year were due to the following (in thousands):

Change From Prior Year Three Months Nine Months
Legal expenses(a) $(838) $(1,358)
Intangible asset amortization(b) 268 1,512
Incentive compensation programs(c) 1,884 5,111
Transition services agreement(d) (1,834) (1,834)
Other(e) (453) (1,135)
Net increase (decrease) in SG&A Expenses $(973) $2,296

(a) Amount represents the change in legal costs compared to the prior year period, including legal expenses incurred related to our on-going patent infringement case. Refer to Note 10 “Commitments and Contingencies” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for information related to this patent infringement litigation.

(b) Amount represents the increase in intangible asset amortization (i.e. customer list), which is amortized based upon the forecasted cash flows at the time of acquisition for the respective asset.

(c) Amount represents the impact to our SG&A attributable to our cash and stock incentive programs, including performance-based compensation, which is accrued based upon actual results achieved.

(d) Represents the amount included in SG&A Expenses, which was charged to Viant for transition services provided for the three months ended September 28, 2018. We executed a transition services agreement in conjunction with the sale of the AS&O Product Line, whereby we will provide certain corporate services (including accounting, payroll, and information technology services) to Viant for a period of up to one year from the date of the closing to facilitate an orderly transfer of business operations.

(e) Represents various increases and decreases to our SG&A.

RD&E

Changes to RD&E expenses from the prior year were due to the following (in thousands):

Change From Prior Year Three Months Nine Months
Intangible asset amortization(a) $(98) $(293)
Incentive compensation programs(b) 389 1,120
Other(c) (284) 2,514
Net increase in RD&E $7 $3,341

(a) Amount represents the decrease in intangible asset amortization, which is amortized based upon the forecasted cash flows at the time of acquisition for the respective asset.

(b) Amount represents the impact to our RD&E attributable to our cash and stock incentive programs, including performance-based compensation, which is accrued based upon actual results achieved.

(c) Represents the net impact of various increases and decreases to our RD&E. RD&E expense for the third quarter and first nine months of 2018 reflects our increased investment in projects with a higher growth opportunity.

  • 45 -

Other Operating Expenses

Refer to “Cost Savings and Consolidation Efforts” section of this Item and Note 8 “Other Operating Expenses” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further information related to these initiatives. Other Operating Expenses is comprised of the following (in thousands):

Three Months Ended September 28, 2018 September 29, 2017 Nine Months Ended September 28, 2018 September 29, 2017
Strategic reorganization and alignment(a) $2,643 $— $8,424 $—
Manufacturing alignment to support growth(b) 877 — 2,493 —
Consolidation and optimization costs(c) 137 2,979 698 8,055
Acquisition and integration expenses(d) — 2,267 — 10,057
Asset dispositions, severance and other(e) 482 823 1,000 6,378
Total other operating expenses $4,139 $6,069 $12,615 $24,490

(a) As a result of the strategic review of our customers, competitors and markets we undertook during the fourth quarter of 2017, we began to take steps to better align our resources in order to invest to grow, protect, preserve and to enhance the profitability of our portfolio of products. This will include focusing our investment in RD&E and manufacturing, improving our business processes and redirecting investments away from projects where the market does not justify the investment. As a result, during the first nine months of 2018, we incurred charges related to this strategy, which primarily included severance costs and fees for professional services.

(b) In 2017, we initiated several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of our facilities.

(c) During 2018 and 2017, we incurred costs primarily related to the closure of our Clarence, NY facility and the transfer of our Beaverton, OR portable medical and Plymouth, MN vascular manufacturing operations to Tijuana, Mexico.

(d) Reflects acquisition and integration costs related to the acquisition of Lake Region Medical, which occurred in October 2015. This initiative was substantially complete as of December 29, 2017.

(e) Amounts for 2017 primarily include expenses related to our CEO and CFO transitions.

We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion. For 2018, Other Operating Expenses is expected to be approximately $15 million to $20 million. Refer to the “Cost Savings and Consolidation Efforts” section of this Item for further details on these initiatives.

  • 46 -

Interest Expense

Interest Expense for the three and nine months ended September 28, 2018 was $54.5 million and $85.4 million, respectively, compared to $15.8 million and $49.2 million for the three and nine months ended September 29, 2017. The weighted average interest rates paid on outstanding borrowings for the three and nine months ended September 28, 2018 was 4.95% and 4.97%, respectively, compared to 4.72% and 4.67%, for the comparable periods in 2017. The weighted average interest rates paid in the third quarter and first nine months of 2018 reflect an increase in LIBOR during 2017 and 2018, partially offset by a cumulative 125 basis point and 75 basis point reduction to the applicable interest rate margins of our Term Loan B and Term Loan A facilities. The Term Loan B margin decrease resulted from amendments of our Senior Secured Credit Facilities in March 2017 and again in November 2017, and the step down in the third quarter of 2018 resulting from the upgrade of our corporate family credit rating, while the Term Loan A decrease resulted from contractual reductions due to our lower leverage ratio. Cash interest expense decreased $1.1 million and $2.4 million for the three and nine months ended September 28, 2018, respectively, when compared to the same periods in 2017. Non-cash interest expense (i.e. deferred fee and discount amortization) increased $39.8 million and $38.6 million for the three and nine months ended September 28, 2018, respectively, when compared to the same period in 2017, primarily attributable to higher accelerated write-offs (losses from extinguishment of debt) of deferred fees and original issue discount related to prepayments of portions of our Term Loan B facility and Senior Notes during the respective periods and a “make-whole” premium of $31.3 million paid as a result of redeeming our Senior Notes in July 2018. We recognized losses from extinguishment of debt during the three and nine months ended September 28, 2018 of $40.7 million and $42.1 million, respectively. We repaid $595.0 million of debt during the third quarter of 2018 and $670.1 million during the first nine months of 2018. See Note 5 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our debt.

(Gain) Loss on Cost and Equity Method Investments, Net

The Company holds investments in equity and other securities that are accounted for as either cost method or equity method investments. During the three and nine months ended September 28, 2018, we recognized net gains of $0.3 million and $5.5 million, respectively, compared to a net gain of $1.9 million and a net loss of $2.9 million for the three and nine months ended September 29, 2017, respectively, on our cost and equity method investments. The Company did not recognize any impairment charges related to cost method investments during the nine months ended September 28, 2018. The three and nine months ended September 29, 2017 included impairment charges of $0.3 million and $5.3 million, respectively, recognized on our cost method investments. Our cost method investments are in start-up research and development companies whose fair value is highly subjective in nature and could be subject to significant fluctuations in the future that could result in material gains or losses. See Note 13 “Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our cost and equity method investments.

Other Loss, Net

Other Loss, Net for the three and nine months ended September 28, 2018 was $1.7 million and $0.3 million, respectively, compared to other loss of $2.5 million and $10.7 million for the three and nine months ended September 29, 2017. Other Loss, Net is primarily comprised of income (loss) from the impact of foreign currency exchange rates on transactions denominated in foreign currencies.

Our foreign currency transaction gains/losses are based on fluctuations of the U.S. dollar relative to the Euro or Peso. The impact of foreign currency exchange rates on transactions denominated in foreign currencies included in Other Loss, Net for the three and nine months ended September 28, 2018 were losses of $1.7 million and $0.8 million, respectively, compared to a losses of $2.5 million and $10.6 million for the three and nine months ended September 29, 2017, respectively. We continually monitor our foreign currency exposures and seek to take steps to mitigate these risks. However, fluctuations in foreign currency exchange rates could have a significant impact, positive or negative, on our financial results in the future.

Provision for Income Taxes

We recognized income tax benefit of $6.2 million for the third quarter of 2018 on $14.5 million of pre-tax loss from continuing operations compared to income tax benefit of $0.4 million on $19.4 million of pre-tax income from continuing operations for the same period of 2017. The income tax expense for the first nine months of 2018 was $7.9 million on income from continuing operations before taxes of $35.8 million compared to $0.6 million on $33.0 million of income from continuing operations before taxes for the same period of 2017.

  • 47 -

We expect continued volatility in our effective tax rate due to several factors including: changes in the mix of pre-tax income from continuing operations and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. We continuously evaluate and currently have various tax planning initiatives in place that are aimed at reducing our effective tax rate over the long term.

Our worldwide effective tax rate is expected to be approximately 32% for 2018, excluding discrete items. Our effective tax rate for 2018 differs from the U.S. federal statutory tax rate of 21% due principally to the estimated impact of the GILTI tax. Our earnings outside the U.S. are generally taxed at blended rates that are marginally lower than the U.S. federal rate. The GILTI provisions require us to include foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in our U.S. income tax return. There is a statutory deduction of 50% of the GILTI inclusion, however the deduction is subject to limitations based on U.S. taxable income. We currently have NOLs to offset forecasted U.S. taxable income and as such, are temporarily subject to the deduction limitation, which correspondingly imposes an incremental impact on U.S. income tax. The foreign jurisdictions in which we operate and where our foreign earnings are primarily derived, include Switzerland, Mexico, Uruguay, Malaysia and Ireland. While we are not currently aware of any material trends in these jurisdictions that are likely to impact our current or future tax expense, our future effective tax rates could be adversely affected by earnings being lower than anticipated in countries where we have lower effective tax rates and higher than anticipated in countries where we have higher effective tax rates, or by changes in tax laws or regulations. We regularly assess any significant exposure associated with increases in tax rates in international jurisdictions and adjustments are made as events occur that warrant adjustment to our tax provisions.

Our 2018 blended effective tax rate on foreign earnings is currently estimated to be approximately 15% for continuing operations. For the year, we expect to have positive income before taxes in our foreign jurisdictions but losses before taxes in U.S. jurisdictions due to our projected amounts of Interest Expense.

Liquidity and Capital Resources

(dollars in thousands)

September 28, 2018 December 29, 2017
Cash and cash equivalents $22,881 $37,341
Working capital 250,677 263,863
Current ratio 2.41 2.64

Cash and cash equivalents at September 28, 2018 decreased by $14.5 million from year-end as excess cash on hand was used to pay down our debt. Working capital from continuing operations decreased by $13.2 million from December 29, 2017, primarily due to the reduced cash balances.

At September 28, 2018, $10 million of our cash and cash equivalents were held by foreign subsidiaries. We intend to limit our distributions from foreign subsidiaries to previously taxed income. If distributions are made utilizing current period earnings, we will record foreign withholding taxes in the period of the distribution.

Summary of Cash Flow

(in thousands)

Cash provided by (used in): Nine Months Ended September 28, 2018 September 29, 2017
Operating activities $120,736 $115,570
Investing activities 549,155 (34,702)
Financing activities (692,896) (91,317)
Effect of foreign currency exchange rates on cash and cash equivalents 1,790 1,970
Net change in cash and cash equivalents $(21,215) $(8,479)

The cash flow information presented includes cash flows related to the discontinued operations.

  • 48 -

Operating Activities – During the nine months ended September 28, 2018, we generated cash of $120.7 million from operations compared to $115.6 million for the nine months ended September 29, 2017. This increase was primarily due to a $26.4 million increase in cash income (i.e. income from continuing operations plus adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities) partially offset by a $21.2 million decrease in cash flow provided by working capital. The cash flow from working capital change during the period was primarily due to lower accrued interest as a result of our lower debt levels.

Investing Activities – The $583.9 million increase in cash flows from investing activities was primarily attributable to net cash proceeds from the sale of the AS&O Product Line of approximately $582 million. Our current expectation is that capital spending for continuing operations for 2018 will be in the range of $37 million to $42 million, of which approximately half is discretionary in nature. We anticipate that cash on hand, cash flows from operations and available borrowing capacity under our Revolving Credit Facility will be sufficient to fund these capital expenditures. Property, plant, and equipment purchases related to our AS&O Product Line were approximately $15 million per year.

Financing Activities – Net cash used in financing activities for the first nine months of 2018 was $692.9 million compared to $91.3 million in the comparable 2017 period. Financing activities during the first nine months of 2018 included net payments of $670.1 million related to paying down our debt obligations compared to $106.5 million for the comparable 2017 period.

In connection with the completion of the sale of our AS&O Product Line, during the third quarter of 2018 we repaid $548 million of our debt, which included $360 million of our 9.125% Senior Notes, $114 million of our Term Loan B Facility and $74 million outstanding on our Revolving Credit Facility.

Capital Structure – As of September 28, 2018, our capital structure consists of $954 million of debt outstanding under our Senior Secured Credit Facilities and 33 million shares of common stock outstanding. We have access to $191 million of borrowing capacity under our Revolving Credit Facility. We are also authorized to issue up to 100 million shares of common stock and 100 million shares of preferred stock. Our debt service obligations, comprised of principal and interest payments for the remainder of 2018, are estimated to be approximately $22 million.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and potential borrowings under the Revolving Credit Facility should be sufficient to meet our working capital and fixed capital requirements for the next twelve months. If our future financing needs increase, we may need to arrange additional debt or equity financing. Accordingly, we evaluate and consider from time to time various financing alternatives to supplement our financial resources and optimize our capital structure. We cannot be assured that, if needed, we will be able to enter into any such arrangements on acceptable terms or at all.

Credit Facilities - As of September 28, 2018, we had senior secured credit facilities (the “Senior Secured Credit Facilities”) that consist of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”), which had letters of credit totaling $9 million drawn against it as of September 28, 2018, (ii) a $314 million term loan A facility (the “TLA Facility”), and (iii) an $658 million term loan B facility (the “TLB Facility”). The Revolving Credit Facility will mature on October 27, 2020, the TLA Facility will mature on October 27, 2021 and the TLB Facility will mature on October 27, 2022.

The Revolving Credit Facility and TLA Facility contain financial covenants requiring (A) a maximum total net leverage ratio (as defined in the agreement governing the Senior Secured Credit Facilities) of 5.75:1.0, subject to periodic step downs beginning in the fourth fiscal quarter of 2018 and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of 2.75:1.0 subject to a step up beginning in the first quarter of 2019. As of September 28, 2018, our total net leverage ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 3.4 to 1.00. For the twelve month period ended September 28, 2018, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 5.4 to 1.0.

Failure to comply with these financial covenants would result in an event of default as defined under the Revolving Credit Facility and TLA Facility unless waived by the lenders. An event of default may result in the acceleration of our indebtedness. As a result, management believes that compliance with these covenants is material to us. As of September 28, 2018, we were in full compliance with the financial covenants described above. However, a significant increase in the LIBOR interest rate or a decline in our operating performance, and in particular our sales or adjusted EBITDA, could result in our inability to meet these financial covenants and lead to an event of default if a waiver or amendment could not be obtained from our lenders. The Revolving Credit Facility is supported by a consortium of thirteen lenders with no lender controlling more than 27% of the facility.

Upon completion of the redemption in full of the Senior Notes in July 2018, the indenture governing the Senior Notes was satisfied and discharged. See Note 5 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further information on the Company’s outstanding debt.

  • 49 -

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission, or other authoritative accounting bodies to determine the potential impact they may have on our Condensed Consolidated Financial Statements. See Note 16 “Impact of Recently Issued Accounting Standards” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.

Contractual Obligations

Presented below is a summary of contractual obligations as of September 28, 2018, reflecting the redemption in full of the Senior Notes, repayment of our Term Loan B Facility and Revolving Credit Facility during the third quarter of 2018.

Payments due by period Total Less than 1 year 1-3 years 3-5 years More than 5 years
Total debt obligations $972,349 $37,500 $75,000 $859,849 $—
Interest on debt(a) 174,548 47,612 89,891 37,045 —

(a) Interest payments in the table above reflect the contractual interest payments on our outstanding debt based upon the balance outstanding and applicable interest rates at September 28, 2018, and exclude the impact of the debt discount amortization and impact of interest rate swap agreements.

Refer to Note 5 “Debt” and Note 10 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for further discussion on our contractual obligations.

Critical Accounting Policies and Estimates

The preparation of our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Our estimates, assumptions and judgments are based on historical experience and various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities that are not readily apparent from other sources. Making estimates, assumptions and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Management believes the estimates, assumptions and judgments employed and resulting balances reported in the Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially.

There have been no significant changes to the critical accounting policies and estimates as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 29, 2017.

  • 50 -

Market risk

As filed, 541 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Refer to information appearing under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-Q. Furthermore, a discussion of market risk exposures is included in Part II, Item 7A, Quantitative and Qualitative Disclosure about Market Risk, of the Company’s Annual Report on Form 10-K for the year ended December 29, 2017. There have been no material changes in reported market risk since the inclusion of this discussion in the Company’s Annual Report on Form 10-K referenced above.

Controls and procedures

As filed, 1,421 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

a. Evaluation of Disclosure Controls and Procedures

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the Securities and Exchange Commission as of September 28, 2018. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Based on their evaluation, as of September 28, 2018, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting

During the Company’s most recent fiscal quarter, there have been no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

  • 51 -

Risk factors

As filed, 171 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes to the Company’s risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 29, 2017.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-09-28. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-06-30 to 2018-09-28$305.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2017-12-30 to 2018-09-28$912.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2018-06-30 to 2018-09-28$213.2mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2017-12-30 to 2018-09-28$637.8mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2018-06-30 to 2018-09-28$91.9mus-gaap:GrossProfit
Gross profit9 months2017-12-30 to 2018-09-28$274.2mus-gaap:GrossProfit
Selling, general and administrative3 months2018-06-30 to 2018-09-28$34.1mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2017-12-30 to 2018-09-28$107.3mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2018-06-30 to 2018-09-28$41.5mus-gaap:OperatingIncomeLoss
Operating income9 months2017-12-30 to 2018-09-28$115.9mus-gaap:OperatingIncomeLoss
Interest expense3 months2018-06-30 to 2018-09-28$54.5mus-gaap:InterestExpense
Interest expense9 months2017-12-30 to 2018-09-28$85.4mus-gaap:InterestExpense
Income tax3 months2018-06-30 to 2018-09-28−$6.2mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2017-12-30 to 2018-09-28$8.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2018-06-30 to 2018-09-28$114.1mus-gaap:NetIncomeLoss
Net income9 months2017-12-30 to 2018-09-28$142.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-06-30 to 2018-09-28$3.54us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2017-12-30 to 2018-09-28$4.38us-gaap:EarningsPerShareDiluted
Basic EPS3 months2018-06-30 to 2018-09-28$3.54us-gaap:EarningsPerShareBasic
Basic EPS9 months2017-12-30 to 2018-09-28$4.44us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2018-06-30 to 2018-09-2832,211,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2017-12-30 to 2018-09-2832,451,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2017-12-30 to 2018-09-28$120.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2017-12-30 to 2018-09-28$33.3mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-09-28$22.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-09-28$428.7mus-gaap:AssetsCurrent
Total assetsAt period end2018-09-28$2.36bnus-gaap:Assets
Current liabilitiesAt period end2018-09-28$178.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-09-28$1.32bnus-gaap:Liabilities
Long-term debtAt period end2018-09-28$916.7mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2018-09-28$37.5mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2018-09-28$1.04bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001114483-18-000026. Last ingested by Listed: Nov 11, 2026, 00:08 ET. Listed shows no prices and gives no investment advice.